However, as we enter 2026, the next big AI supercycle may be emerging. The first phase was largely about generative AI. This includes chatbots like OpenAI's ChatGPT, Anthropic's Claude, and Alphabet ...
The rate at which agentic AI is entering the contemporary workplace is, bluntly, staggering it is, in fact, unprecedented in ...
Discover the leading robotic process automation tools for enterprises in 2025 that enhance digital transformation, reduce costs, and increase efficiency. Learn about RPA software features and pricing ...
The AI orchestration platform is seeing its revenue accelerate. However, the company is just starting to tap into its potential. Meanwhile, the stock is still cheap despite its recent surge. For those ...
This article first appeared on GuruFocus. UiPath (NYSE:PATH) shares surged more than 8% on early Thursday after the company topped expectations with its third-quarter results and gave upbeat guidance.
UiPath offers attractive AI automation exposure at a compelling valuation, with shares up ~35% YTD and strong Q3 results fueling momentum. PATH trades at 4.6x EV/FY27 revenue and 18.3x EV/FY27 FCF, ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
James Chen, CMT is an expert trader, investment adviser, and global market strategist. David Kindness is a Certified Public Accountant (CPA) and an expert in the fields of financial accounting, ...
Jennifer Simonson is a business journalist with a decade of experience covering entrepreneurship and small business. Drawing on her background as a founder of multiple startups, she writes for Forbes ...
Process chemistry involves the development and optimization of production processes for chemical compounds, and the scaling up of laboratory reactions, particularly in the pharmaceutical sector. The ...